1. Давыдов М.И., Полоцкий Б.Е. Рак легкого — М.: Радикс, 1994. — 206 с.
2. Трахтенберг А.Х., Чиссов В.И. Клиническая онколопульмонология — М.,
3. The Health Consequences of Smoking: A Report of the Surgeon General (ed 2010/07/30). Atlanta (GA): U.S. Department of Health and Human Services. Centers for Disease Controland Prevention (US), 2004.
4. Goldstraw P. Staging Manual in Thoracic Oncology. An International Association for the Study of Lung Cancer Publication, 2009.
5. Fossella F.V., Putnam J.B., Komaki R., eds. Lung Cancer. M.D. Andersen Cancer Care Serires. New York: Springer; 2003: 316.
6. Schrump D.S., Carter D., Kelsey C.R. et al. Non-small cell lung cancer. In DeVita Jr. VT, Lawrence T.S., Rosenberg S.A. et al., eds. DeVita, Hellman, and Rosenberg Cancer; Prinsiples and Practice of Oncology. Philadelphia; Lippincott Williams and Wilkins, 2011.
7. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого T1-2N0M0 // Вопр. онкол. 2015 — Т. 61, № 3. — С. 413-417.
8. Gopaldas R.R., Bakaeen F.G., Dao T.K. et al. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13619 patients // Ann. Thorac. Surg. — 2010. — Vol. 89, № 5. — P. 1563-1570.
9. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after videoassisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer // J. Cardiothorac. Surg. — 2014. — Vol. 9. — P. 88-92.
10. Naruke T. Lymph node metastasis of lung cancer and associated surgery // Asian Medical Journal. — 1990. — V. 33, № 12. — H. 668-677.
11. Paul S., Altorki N.K., Sheng S. et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database // J. Thorac. Cardiovasc. Surg. — 2010. — Vol. 139. — P. 366-378.
12. Scott W.J., Allen M.S., Darling G. et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial // J. Thorac. Cardiovasc. Surg. — 2010. — Vol. 139. — P. 976-981.
13. Ginsberg R.J., Rubinstein L.V. Randomised trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer // Ann. Thorac. Surg. — 1995. — Vol. 60. — P. 615-622.
14. Arriagada R., Bergman B., Dunant A. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer // N. Engl. J. Med. — 2004; 350: P. 351-360.
15. Winton T., Livingston R., Johnson D. et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer // N. Engl. J. Med. — 2005; 352. — P. 2589-2597.
16. Douillard J.Y., Rosell R., De Lena M. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-smallcell lung cancer (ANITA): a randomized controlled trial // Lancet Oncol. — 2006: 7. — Р. 719-727.
17. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al. Randomized phase III study of surgery alone or surgery plus preoperativw cisplatin and gemcitabine in stages IB to IIIA non-small-celllung cancer // J. Clin. Oncol. — 2012; 30. — P. 172-178.
18. Curran W.J., Paulus R., Langer C.J. et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410 // J. Natl. Cancer Inst. — 2011; 103. P. 1452-1460.
19. Masters G.A., Temin S., Azzoli C.G. et al. Systemic Therapy for Stage IV NonSmall0Cell Lung Cancer. American Society of Clinical Oncology. Clinical Practice Guideline Update // J. Clin. Oncol. — 2015; 33. — P. 3488-3515.
20. Burroto M., Manasanch E.E., Wilkerson J., Fojo T. Gefitinib and erlotinib in metastatic non-small-cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials // Oncologist. — 2015; 20. — P. 400-410.
21. Sequst L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations // J. Clin. Oncol. — 2013: 31:3327-3334.
22. WHO Classification of Tumours of the Lung. — Pleura, Thymus and Heart, 2015.
23. Solomon B.J., Mok T., Kim D.W. et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer // N. Engl. J. Med. — 2013; 371: 2167-2177.
24. Costa D.B., Shaw A.T., Ou S.H. et al. Clinical Experience With Crisotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases // J. Clin. Oncol. — 2015; 33: 1881-1888.
25. Camidge D.R., Bang Y.U., Kwak E.L. et al. Activity and safety of crisotinib in patients with ALK-positive non-small-cell lung cancer, updated results from a phase 1 stud // Lancet Oncol. — 2012; 13: 1011-1019.
26. Shaw A.T., Yeap B.Y., Solomon B.J. et al. Impact of crisotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls [abstract] // J. Clin. Oncol. — 2011; 29 (Suppl 15): Abstract 7507.
27. Scagliotti G.V., Parikh P., von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced— stage non-small-cell lung cancer // J. Clin. Oncol. — 2008; 26: 3543-3551.
28. D. Addario G., Pintile M., Leighi N.B. et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of published literature // J. Clin. Oncol. — 2005; 23: 2926-2936.